Search Results - small+molecules

132 Results

Sort By:

Gut-specific serotonin transporter inhibitors for treatment of constipation

Value Proposition· Potent inhibition of serotonin transporter (SERT) in GI system· Luminally and or/peripherally-restricted SERT inhibitors· Result in enhanced action of serotonin in stimulation of GI motility· Spares the body of systemic and CNS effectsUnmet NeedConstipation-predominant IBS involves reduced gastrointestinal...

Published: 3/13/2025 | Inventor(s): Pankaj Pasricha, James Barrow, Qian Li, Pablo de Leon, Yifang Huang

Keywords(s): Antagonists/Inhibitors, Biomarker, Disease Indication, Gastrointestinal Disorders, Mechanism-of-action Biomarker, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Gastroenterology

Novel Oxazolidinones for Treatment of Bacterial Infections

Marketing Summary DraftNovel Oxazolidinones for Treatment of Bacterial InfectionsJHU Ref #: C14633Value Proposition· Belong to the same chemical family as Zyvox, marketed by Pfizer, but shows better efficacy· Positive activity demonstrated against M. tuberculosis· MIC values the same or better than the current antibiotics in the...

Published: 3/13/2025 | Inventor(s): Gyanu Lamichhane, J. Ippoliti

Keywords(s): Bacterial Infections, Disease Indication, Infectious Diseases, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections

Small Molecule Neutral Sphingomyelinase 2 (nSMase2) Inhibitors

Unmet NeedNeutral sphingomyelinase 2 (nSMase2) is expressed in neurons and hydrolyzes sphingomyelin, producing the lipid ceramide, which functions in stress responses leading to apoptosis, cell growth arrest, and differentiation. Increased levels of ceramides have been associated with many neurological disorders, including Alzheimer’s disease, multiple...

Published: 3/14/2025 | Inventor(s): Takashi Tsukamoto, Niyada Hin, Ondrej Stepanek, Barbara Slusher, Camilo Rojas, Ajit Thomas

Keywords(s): Antagonists/Inhibitors, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules

Inhibition of nSMase for the Treatment of Human Immunodeficiency Virus Infection

Unmet NeedHuman immunodeficiency virus (HIV) is a retrovirus that negatively impacts the immune system, leading to immunosuppression and increased susceptibility to secondary, opportunistic infections and some cancers. It is estimated that 36.7 million people worldwide are currently living with HIV. Presently, HIV has no cure and requires life-long...

Published: 3/13/2025 | Inventor(s): Norman Haughey, Barbara Slusher, Camilo Rojas

Keywords(s): Antagonists/Inhibitors, Disease Indication, HIV, Infectious Diseases, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases > HIV

Discovery of Small Molecule Inhibitors of Neutral Sphingomyelinase 2 (nSMase2) for the Treatment of Neurodegenerative Diseases

Unmet NeedIn the brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increased activity and expression of this enzyme has been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Inhibition of human nSMase2 may preserve neuronal function...

Published: 3/13/2025 | Inventor(s): Barbara Slusher, Camilo Rojas, Ajit Thomas, Radim Nencka, Michal Sala, Hubert Hrebabecky, Norman Haughey

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, Assay, Clinical Diagnostics, CNS and Neurological Disorders, Disease Indication, In Vitro Diagnostics, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Alzheimer's Disease

Prodrug for Immunological and Oncological Therapy

Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...

Published: 3/14/2025 | Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian

Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules

Treatment of Irritable Bowel Syndrome with Molybdenum

Unmet NeedIrritable Bowel Syndrome is a chronic and incurable gastrointestinal disorder that affects 3-20% of Americans depending on certain sociocultural and comorbid factors. A poorly understood condition, current treatments consist of antispasmodics, antidiarrheals, and dietary restrictions. Unable to alleviate all its symptoms, researchers are in...

Published: 3/13/2025 | Inventor(s): Pankaj Pasricha, Lian Sheng Liu, Qian Li, Alfred Spormann

Keywords(s): Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease (IBD), Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Gastroenterology > Irritable Bowel Disease

Inhibition of rip kinases for treating neurodegenerative disorders

Unmet NeedNeurodegenerative disorders are a heterogeneous group that includes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and Huntington’s disease. These disorders result from progressive degeneration of the structure, function, and network of neurons in the central nervous...

Published: 3/13/2025 | Inventor(s): Seulki Lee, Han Seok Ko, Ted Dawson, Martin Pomper, Donghoon Kim, Yumin Oh, Seung-Hwan Kwon, Yong Joo Park

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Neurodegenerative Diseases, Parkinson's Disease, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 3/13/2025 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Selective Targeting of a Novel Protective Anti-inflammatory Receptor in Human Mitochondria and its Role in Preserving Mitochondrial Functions

Unmet NeedAccording to WHO, over one billion people worldwide are living with elevated blood pressure which may lead to a range of adverse health conditions that cause ~1,100 deaths per day. Many current high blood pressure therapies focus on angiotensin receptor blocking drugs. Unfortunately, adverse events (e.g., renal dysfunction, hyperkalemia, and...

Published: 3/13/2025 | Inventor(s): Andrew Cheetham, Peter Abadir, Jeremy Walston, Honggang Cui

Keywords(s): Antagonists/Inhibitors, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

1 2 3 4 5 6 7 8 9 10 ...